Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance

Journal of Cellular Physiology

Volumn 225, Issue 3, 2010, Pages 822-828

  Shen, Ding Wu ^a   Ma, Jichun ^a   Okabe, Mitsunori ^a   Zhang, Guofeng ^b   Xia, Di ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CARRIER PROTEIN; CISPLATIN; COMPLEMENTARY DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MEMBRANE PROTEIN; POLYCLONAL ANTIBODY; PROTEIN TMEM205; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TMEM205 PROTEIN, HUMAN; TMEM205 PROTEIN, MOUSE; TUMOR MARKER;

ADRENAL GLAND; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA LIBRARY; DNA REPAIR; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOELECTRON MICROSCOPY; LIVER; MOLECULAR CLONING; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTO ONCOGENE; RETROVIRUS; AMINO ACID SEQUENCE; ANIMAL; CELL PROLIFERATION; CELL STRAIN 3T3; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HELA CELL; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PATHOLOGY; TIME; TRANSPORT AT THE CELLULAR LEVEL; UPREGULATION;

ALEXA;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BALB 3T3 CELLS; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; CISPLATIN; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, IMMUNOELECTRON; MOLECULAR SEQUENCE DATA; NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77957731016     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22287     Document Type: Article

References (20)

1. Andrews PA, Velury S, Mann SC, Howell SB. 1988. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48: 68-73.
2. Borst P, Jonkers J, Rottenberg S. 2007. What makes tumors multidrug resistant? Cell Cycle 6: 2782-2787.
3. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. 2006. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58: 384-395.
4. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A. 2003. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: A bioinformatics assessment. Genome Res 13: 2265-2270.
5. Francia G, Man S, Teicher B, Grasso L, Kerbel RS. 2004. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 24: 6837-6849.
6. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
7. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. 2008. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535.
8. Liang XJ, Shen DW, Garfield S, Gottesman MM. 2003. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 63: 5909-5916.
9. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. 1992. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: Circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109-1115.
10. Niedner H, Christen R, Lin X, Kondo A, Howell SB. 2001. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160.
11. Richon VM, Schulte N, Eastman A. 1987. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47: 2056-2061.
12. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW. 2005. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158.
13. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. 2008. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116-1120.
14. Shen D, Pastan I, Gottesman MM. 1998. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58: 268-275.
15. Shen DW, Liang XJ, Suzuki T, Gottesman MM. 2006. Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol 69: 1383-1388.
16. Stewart DJ. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31.
17. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA. 2002. Generation and initial analysis of more than 15, 000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99: 16899-16903.
18. Wang D, Lippard SJ. 2005. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
19. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. 2008. MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
20. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, Tsuruo T, Inazawa J. 2004. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410.